Safety of PERC Tool Validated for Very Low Risk PE Rule Out in ER
WEDNESDAY, Feb. 14, 2018 -- For low risk patients with suspected pulmonary embolism (PE), randomization to eight-item PE rule-out criteria (PERC) seems safe, according to a study published in the Feb. 13 issue of the Journal of the American Medical Association.
Yonathan Freund, M.D., Ph.D., from the Sorbonne Université in Paris, and colleagues conducted a non-inferiority trial in 14 emergency departments in France to validate the safety of PERC-based strategy to rule out PE. A total of 1,916 patients were cluster-randomized: 962 were assigned to the PERC group and 954 to the control group.
The researchers found that a PE was diagnosed at initial presentation in 2.7 percent of patients in the control group, compared with 1.5 percent in the PERC group (difference, 1.3 percent; 95 percent confidence interval, −0.1 to 2.7 percent; P = 0.052). During follow-up, one PE was diagnosed in the PERC group versus none in the control group (difference, 0.1 percent; 95 percent confidence interval, −∞ to 0.8 percent). In the PERC versus the control group, the proportion of patients undergoing computed tomographic pulmonary angiography was 13 versus 23 percent (difference, −10 percent; 95 percent confidence interval, −13 to −6 percent; P < 0.001). Rates were significantly reduced in the PERC group for the median length of emergency department stay and hospital admission.
"These findings support the safety of PERC for very low risk patients presenting to the emergency department," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: February 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.